Loop Genomics Expands Kit and Service Offerings with first tech that combines transcript counting with phasing for mRNA using long-reads on Illumina sequencers

Company deploys new sequencing technology and protocols 

to provide unparalleled insight into transcriptome research

SAN JOSE, California (Mar 5, 2019)- Loop Genomics, the single molecule counting long-read sequencing company with a hardware free solution, has expanded its kit and services capabilities to provide researchers with the first solution that provides both transcript counting and phasing for mRNA using long-reads on Illumina sequencers all from one kit.  With significantly reduced error rates compared to those of PacBio and ONT Loop’s solution allows researchers to accurately determine not only transcript abundance but unique isoforms as well.  

By investing in in-house Illuminasequencing instruments researcher can reduce costs and gain significant insights with a plug and play kit that utilizes low cost core consumables when compared to other long-read platforms.  A lab simply needs to replace their sample prep kits for their RNA experiments with Loop’s sample prep kits.  The company utilized its synthetic long-read platform to create a new kit that answers not one but two fundamental questions that researchers often have in studying gene expression.  Which mRNA isoforms are expressed in any given sample and how many transcripts are present from each of the isoforms.  

Loop Genomics provides an affordable kit ($70/sample), and service ($299/sample) identifying the presence and relative abundance of transcripts and isoform types from a single data stream. In addition, Loop’s pipeline, included in the cost of the kit, not only does the computationally intensive recreation of the long-reads from clouds of short read but also provides actionable reports so researchers can quickly figure out the next experiment they’d like to perform.

According to Tuval Ben Yehezkel PhD, CEO and founder of Loop Genomics, “With early adopters of the technology including Geisinger, Cancer Research UK, Vancouver Prostate Centre and UFL the product is solving immediate needs and generating some very interesting data.  We are proud to continue to leverage our core technology to bring the first kit of its kind to market, and we will continue to translate the latest advances in genetic sequencing into products for researchers in their pursuit of getting better genomic data.”